Revolutionizing Neurotherapeutics for Pain & Alzheimer’s
Elixiria is an innovative biopharmaceutical company dedicated to delivering groundbreaking medicines to address the critical needs of patients with neurological disorders including chronic pains
Pipeline
Team
Brings deep experience in pharmaceutical R&D and a vision for accelerating early-stage therapeutic innovation. Contributed to both academic and industry-based scientific programs at top global life sciences institutions and continues to consult in a non-conflicting capacity. PhD in Biochemistry, over 20 peer reviewed publications in biomedical research.
Morgan Zhang, PhD
Board Chair and Scientific Advisor
Director and Prof. of Anesthesiology, at Univ. of New Mexico. 36 years’ research experience in pain. Published 10 US patents and 200+ papers on pain. Responsible for efficacy studies in pain.
Karin Westlund, PhD
Scientific Advisor and Board Member
Over a decade of venture capital experience, having managed large-scale investment portfolios as Vice President, with expertise in angel investments, venture capital, and private equity. MBA from Zhejiang University, China.
Zhichao Gao
Financial Advisor and Board Member
Unmet Needs in Neurological Diseases
Technological edge of our lead candidate ELB00824
High efficacy of ELB00824 on chemotherapy-induced peripheral neuropathy (CIPN)
IP and Publications
Elixiria’s approved USA and China patent
Publication showing efficacy of ELB00824 in Chemotherapy-induced peripheral neuropathy preclinical models at Neuropharmacology 2022
Publication showing efficacy of ELB00824 in neuropathic pain preclinical models called trigeminal neuropathic pain on Mol Pain 2019
Review on the competitive advantage of ELB00824 over previous PPAR gamma agonists at Molecules 2020
Made with Neo